

(80124)

<b>Medical Benefit</b>		<b>Effective Date:</b> 04/01/13	<b>Next Review Date:</b> 01/18
<b>Preauthorization</b>	Yes	<b>Review Dates:</b> 04/07, 05/08, 01/10, 01/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17	

***Preauthorization is required and must be obtained through Case Management.***

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: • With adult soft tissue sarcomas	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With small cell lung cancer	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With renal cell carcinoma	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With colorectal cancer	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With pancreatic cancer	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With nasopharyngeal cancer	Interventions of interest are: • Hematopoietic stem cell transplantation	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity

## Description

Hematopoietic stem cell transplantation (HSCT) is an established treatment for certain hematologic malignancies and has been investigated for a variety of adult solid tumors. Interest continues in exploring nonmyeloablative allogeneic HSCT for a graft-versus-tumor effect of donor-derived T cells in metastatic solid tumors.

## Summary of Evidence

The evidence for HSCT in individuals who have adult soft tissue sarcomas includes two TEC Assessments, one randomized controlled trial (RCT), and a number of phase 2 single-arm studies, a number of which have been summarized in a Cochrane systematic review. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. The 1995 and 1999 TEC Assessments focusing on HSCT as primary and salvage therapy for a variety of solid tumors found that the available evidence did not permit conclusions about the effect of HSCT on patient survival. Although one small phase 2 study reported longer survival for patients treated with HSCT than standard chemotherapy, the available RCT did not show a survival benefit with HSCT. The evidence is insufficient to determine that autologous HSCT improves outcomes in adults with soft tissue sarcoma.

The evidence for HSCT in individuals who have small cell lung cancer (SCLC) includes two TEC Assessments, several RCTs, and systematic reviews of these studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. The 1995 and 1999 TEC Assessments focusing on HSCT as primary and salvage therapy for a variety of solid tumors found that the available evidence did not permit conclusions about the effect of HSCT on patient survival. Studies published since the TEC Assessments have not reported increased overall survival for patients with SCLC treated with HSCT. The currently available evidence does not support the use of HSCT for SCLC.

The evidence for HSCT in individuals who have renal cell carcinoma, colorectal cancer, pancreatic cancer, or nasopharyngeal cancer includes a TEC Assessment and small single-arm series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. The 1995 and 1999 TEC Assessments focusing on HSCT as primary and salvage therapy for a variety of solid tumors found that the available evidence did not permit conclusions about the effect of HSCT on patient survival. Since publication of the TEC Assessments, the evidence for HSCT in cases of adult soft tissue sarcomas, renal cell carcinoma, colorectal cancer, pancreatic cancer, and nasopharyngeal cancer has been limited to small case series, which are insufficient to demonstrate improved outcomes with autologous or allogeneic HSCT.

## Policy

Autologous or allogeneic hematopoietic stem-cell transplant is considered **investigational** for the following malignancies in adults:

- Lung cancer, any histology
- Colon cancer
- Rectal cancer
- Pancreatic cancer
- Stomach cancer
- Esophageal cancer
- Gall bladder cancer
- Cancer of the bile duct
- Renal cell cancer
- Cervical cancer
- Uterine cancer
- Cancer of the fallopian tubes
- Prostate cancer
- Nasopharyngeal cancer
- Paranasal sinus cancer
- Neuroendocrine tumors
- Soft tissue sarcomas
- Thyroid tumors
- Tumors of the thymus
- Tumors of unknown primary origin
- Malignant melanoma

**Medicare Advantage**

If a transplant is needed, we arrange to have the transplant center review and decide whether the patient is an appropriate candidate for the transplant.

**Background***Hematopoietic Stem Cell Transplantation*

HSCT refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT [allo-HSCT]). They can be harvested from bone marrow, peripheral blood, or from umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in the Placental and Umbilical Cord Blood as a Source of Stem Cells Protocol.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HSCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allo-HSCT. Compatibility is established by typing of human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

Conventional Preparative Conditioning for HSCT

The conventional (“classical”) practice of allo-HSCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is a result of a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include preengraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HSCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility of the patient to opportunistic infections. The immune reactivity between donor T cells and malignant cells that is responsible for the GVM effect also leads to acute and chronic GVHD.

The success of autologous HSCT is predicated on the ability of cytotoxic chemotherapy with or without radiation to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HSCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HSCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning for Allo-HSCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The

goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative, to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HSCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For the purposes of this protocol, RIC will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

#### *HSCT in Solid Tumors in Adults*

HSCT is an established treatment for certain hematologic malignancies. Its use in solid tumors is less well established, although it has been investigated for a variety of solid tumors. With the advent of nonmyeloablative allogeneic transplant, interest has shifted to exploring the generation of alloreactivity to metastatic solid tumors via a graft-versus-tumor effect of donor-derived T cells.<sup>1</sup>

HSCT as a treatment of breast cancer, ovarian cancer, germ cell tumors, or ependymoma is addressed in separate protocols. This protocol collectively addresses other solid tumors of adults for which HSCT has been investigated, including lung cancer; malignant melanoma; tumors of the gastrointestinal tract (affecting the colon, rectum, pancreas, stomach, esophagus, gallbladder, or bile duct); male and female genitourinary systems (e.g., renal cell carcinoma, prostate cancer, cervical cancer, uterine cancer, fallopian tube cancer); tumors of the head and neck; soft tissue sarcoma; thyroid tumors; tumors of the thymus; and tumors of unknown primary origin.

#### **Regulatory Status**

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271.<sup>2</sup> Hematopoietic stem cells are included in these regulations.

#### **Related Protocols**

Hematopoietic Stem Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Hematopoietic Stem Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem Cell Transplantation for Solid Tumors of Childhood

Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell Tumors

Placental and Umbilical Cord Blood as a Source of Stem Cells

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced

procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Carnevale-Schianca F, Ricchiardi A, Capaldi A, et al. Allogeneic hemopoietic stem cell transplantation in solid tumors. *Transplant Proc.* Jul-Aug 2005; 37(6):2664-2666. PMID 16182778
2. (FDA) FaDA. Tissues and Tissue Products. <http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/>. Accessed December 30, 2015.
3. (TEC). BCaBSATEC. High-Dose Chemotherapy with Autologous Stem-Cell Support for Miscellaneous Solid Tumors In Adults. *TEC Assessments* 1995. 1995; 10(Tab 4).
4. (TEC) BCaBSATEC. Salvage High-Dose Chemotherapy with Allogeneic Stem Cell Support for Relapse Following High-Dose Chemotherapy with Autologous Stem Cell Support for Non-lymphoid Solid Tumors. *TEC Assessments* 1999. 1999; 14(Tab 11).
5. Pedrazzoli P, Ledermann JA, Lotz JP, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. *Ann Oncol.* 2006; 17(10):1479-1488.
6. Network NCC. NCCN Guidelines Version 1.2015 Soft Tissue Sarcoma. 2015; [http://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf). Accessed December 30, 2015.
7. Kasper B, Dietrich S, Mechttersheimer G, et al. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. *Oncology.* 2007; 73(1-2):58-64. PMID 18334832
8. Schlemmer M, Wendtner CM, Falk M, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. *Oncology.* 2006; 71(1-2):32-39. PMID 17344669
9. Peinemann F, Labeit AM. Autologous haematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: a Cochrane systematic review. *BMJ Open.* 2014; 4(7):e005033. PMID 25079925
10. Kasper B, Scharrenbroich I, Schmitt T, et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. *Bone Marrow Transplant.* Jul 2010; 45(7):1234-1238. PMID 19935728
11. Hartmann JT, Horger M, Kluba T, et al. A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas. *Invest New Drugs.* Dec 2013; 31(6):1592-1601. PMID 24091981
12. Tsujimura H, Miyaki T, Yamada S, et al. Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation. *Int J Hematol.* Nov 2014; 100(5):507-510. PMID 25062797
13. Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. *J Natl Cancer Inst.* May 4, 2005; 97(9):666-674. PMID 15870437
14. Crivellari G, Monfardini S, Stragliotto S, et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. *Oncologist.* Jan 2007; 12(1):79-89. PMID 17227903
15. Jiang J, Shi HZ, Deng JM, et al. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. *Lung Cancer.* Aug 2009; 65(2):214-218. PMID 19118919

16. Nishimura M, Nasu K, Ohta H, et al. High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation. *Cancer*. Nov 1 1999; 86(9):1827-1831. PMID 10547557
17. Airoidi M, De Crescenzo A, Pedani F, et al. Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. *Head Neck*. Sep 2001; 23(9):799-803. PMID 11505492
18. Lee JA, Choi SY, Kang HJ, et al. Treatment outcome of osteosarcoma after bilateral retinoblastoma: a retrospective study of eight cases. *Br J Ophthalmol*. Oct 2014; 98(10):1355-1359. PMID 24795337
19. Imanguli MM, Childs RW. Hematopoietic stem cell transplantation for solid tumors. *Update Cancer Ther*. 2006; 1(3):343-352.
20. Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. *Nat Clin Pract Oncol*. May 2008; 5(5):256-267. PMID 18398414
21. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med*. Sep 14 2000; 343(11):750-758. PMID 10984562
22. Network NCC. NCCN Guidelines Version 2.2016 Kidney Cancer. 2016; [http://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf). Accessed December 30, 2015.
23. Bregni M, Bernardi M, Servida P, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. *Bone Marrow Transplant*. Aug 2009; 44(4):237-242. PMID 19234510
24. Aglietta M, Barkholt L, Schianca FC, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. *Biol Blood Marrow Transplant*. Mar 2009; 15(3):326-335. PMID 19203723
25. Kanda Y, Omuro Y, Baba E, et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. *Bone Marrow Transplant*. 2008; 42(2):99-103.
26. Abe Y, Ito T, Baba E, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. *Pancreas*. 2009; 38(7):815-819.
27. Toh HC, Chia WK, Sun L, et al. Graft-vs.-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. *Bone Marrow Transplant*. Apr 2011; 46(4):573-579. PMID 20661236
28. Network NCC. NCCN Clinical Practice Guidelines in Oncology. 2015; [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Accessed December 30, 2015.
29. Transplantation ASfBaM. Guidelines, Policy Statements and Reviews. <http://www.asbmt.org/?GuidelineStatements>. Accessed December 30, 2015.